No profile data available.
Biostax Corp. (BTAX) is a healthcare company in the immunodeficiency treatment drugs industry, based in Winter Park, United States.
It reported revenue of $0 for fiscal year 2023, and net income of -$2.36 million. In Q3 2024 (the quarter ended September 30, 2024) revenue was $0. Its market capitalization was $15,742 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS).
Biostax reported $0 in revenue for fiscal year 2023. In Q3 2024 revenue was $0.
$15,742 as of October 8, 2026.
Listed companies of a similar size in the same industry (immunodeficiency treatment drugs) include X4 Pharmaceuticals, Inc. (XFOR), AIM ImmunoTech Inc. (AIM), Enzolytics, Inc. (ENZC).